Interim Report January–September 2023
ChromoGenics increases order intake and continues to lower costsQ3 2023 (July–September) · Net sales amounted to SEK 1.6 (3.5) million, a decrease of SEK 1.9 million compared to the corresponding quarter in 2022. · Operating costs excluding depreciation and amortization and financial expenses amount to SEK 12.2 (22.0) million in Q3 2023 and correspond to a decrease in costs of SEK 9.7 million or 44 percent. · Earnings before tax, depreciation/amortization and financial items (EBITDA) improved in the quarter by SEK 2.5 million and amount to SEK -9.2 (-11.7) million. · Cash flow